Eli Lilly's stock is being viewed as a potential buy following the company's earnings report. Some outlets are suggesting the stock has a path to significant upside, with one noting a possible 30% increase, while others point to institutional investors remaining bullish on the company. However, the overall outlook may be mixed, with some signals potentially conflicting with the generally positive views on Eli Lilly's stock.